A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma

A study to bank samples for future evaluation to identify genetic mutations and other
biomarkers that predispose inflammatory bowel disease (IBD) patients to developing
Hepatosplenic T-cell Lymphoma (HSTCL).

Inclusion Criteria:

- Male or female who has received a single dose of HUMIRA prior to a confirmed diagnosis
of HSTCL.

- Confirmed diagnosis of CD or UC as documented by a Gastroenterologist or physician who
diagnosed the CD or UC.

- Confirmed diagnosis of HSTCL as determined by a biopsy performed on a specimen taken
from the patient.

- Patients 18 years old and older must voluntarily sign and date an IRB/EC approved
Informed Consent Form. For patients younger than 18 years old, a parent or legal
guardian is required to voluntarily sign and date an IRB/EC approved Informed Consent
Form. Pediatric patients will be included in all discussions if possible, in order to
obtain their assent.

Exclusion Criteria:

- Male or female who has not received at least a single dose of adalimumab prior to a
confirmed diagnosis of HSTCL.

- Unconfirmed diagnosis of HSTCL, CD or UC, respectively.

- The patient or the patient's HCP is unwilling to participate in this study.

- The parents or legal guardians (in the case of patients younger than 18 years of age),
who are unable and/or unwilling to consent to the patient's participation in this
study.